770-17-2

Usage

Uses

Used in Pharmaceutical and Biomedical Applications:
2-morpholin-4-ylacetohydrazide is used as an antimicrobial and antifungal agent for its ability to inhibit the growth of certain bacteria and fungi, which can be beneficial in treating infections and preventing contamination in medical settings.
Used in Chemical and Material Industries:
2-morpholin-4-ylacetohydrazide is used as a corrosion inhibitor to protect materials from degradation in various industrial applications, enhancing the durability and longevity of equipment and structures exposed to corrosive environments.

InChI:InChI=1/C6H13N3O2/c7-8-6(10)5-9-1-3-11-4-2-9/h1-5,7H2,(H,8,10)

Upstream product

• 3235-82-3 N-morpholylacetic acid ethyl ester 
• 35855-10-8 methyl 2-morpholin-4-ylacetate 

Downstream Products

• 92034-92-9 1-(morpholin-4-yl-acetyl)-4-phenyl-semicarbazide 
• 72285-43-9 4-(3-chloro-phenyl)-1-(morpholin-4-yl-acetyl)-thiosemicarbazide 
• 72285-44-0 4-(2-methoxy-phenyl)-1-(morpholin-4-yl-acetyl)-thiosemicarbazide 
• 72285-40-6 1-(morpholin-4-yl-acetyl)-4-o-tolyl-thiosemicarbazide 
• 72285-41-7 1-(morpholin-4-yl-acetyl)-4-m-tolyl-thiosemicarbazide 
• 5956-95-6 morpholin-4-yl-acetic acid (2-oxo-2-phenyl-ethylidene)-hydrazide 
• 7037-21-0 morpholin-4-yl-acetic acid (2-biphenyl-4-yl-2-oxo-ethylidene)-hydrazide 
• 72606-35-0 morpholin-4-yl-acetic acid (2,3,5,6-tetramethyl-benzylidene)-hydrazide 
• 7037-26-5 morpholin-4-yl-acetic acid [2-oxo-2-(4-phenoxy-phenyl)-ethylidene]-hydrazide 
• 6592-87-6 morpholin-4-yl-acetic acid [2-oxo-2-(4-phenylsulfanyl-phenyl)-ethylidene]-hydrazide 
• 72285-42-8 4-(2-chloro-phenyl)-1-(morpholin-4-yl-acetyl)-thiosemicarbazide 
• 72285-46-2 4-(4-iodo-phenyl)-1-(morpholin-4-yl-acetyl)-thiosemicarbazide 
• 72285-48-4 5-morpholin-4-ylmethyl-4-m-tolyl-2,4-dihydro-[1,2,4]triazole-3-thione 
• 72285-47-3 5-morpholin-4-ylmethyl-4-o-tolyl-2,4-dihydro-[1,2,4]triazole-3-thione 

Relevant academic research and scientific papers

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

Synthesis of novel Schiff bases and azol-β-lactam derivatives starting from morpholine and thiomorpholine and investigation of their antitubercular, antiurease activity, acethylcolinesterase inhibition effect and antioxidant capacity

In this study, new Schiff bases and β-lactam derivatives containing morpholine and thio morpholine nuclei were synthesized. Antimicrobial, antioxidant, antimicrobial and antioxidant properties of all synthesized compounds were investigated and highly effe

1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6- carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10H-pyrimido[1,2-a][1,8]naphthyridine-6-carboxamide derivative

A new group of 5-(alkylamino)-9-isopropyl[1,2,4]triazolo[4,3-a][1,8] naphthyridine derivatives bearing a CONHR group at the 6-position (1c-g), designed to obtain new effective analgesic and/or anti-inflammatory agents, were synthesized and tested along with three new 9-alkyl-5-(4-alkyl-1-piperazinyl)- N,N-diethyl [1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides (2b-d). Besides, a new class of analogues of compounds 1 and 2, bearing a Mannich base moiety at the 9-position (12a-d), as well as the novel N,N-diethyl-5- (isobutylamino)-8-methyl-10-oxo-10H-pyrimido[1,2-a][1,8]naphthyridine-6- carboxamide (15) were prepared and tested. Compounds 1c-g exhibited very interesting anti-inflammatory properties in rats, whereas compounds 2b-d and 15 proved to be endowed with prevalent analgesic activity frequently associated with sedative effects in mice. On the contrary, the Mannich bases 12a-d resulted inactive. The most effective (80% inhibition of oedema) and potent (threshold dose 1.6 mg kg-1 with 31% inhibition of oedema) anti-inflammatory compound 1d did not show gastrolesive effects following 100 mg kg-1 oral administration in rats.

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives

The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein the definition of substituents is described in the claims. This class of compounds shows high affinity

Methods of treating diseases and disorders by targeting multiple kinases

The present invention is directed to the use of single agents, which are compounds that target two or more kinases simultaneously, thus substantially avoiding resistance to therapy. The invention provides methods for the use for, administration to, and tr

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.